Zevra Therapeutics, Inc. (ZVRA) Income Statement
ZVRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsZVRA revenue and net income
Where ZVRA's revenue goes
2025Each bar shows an amount and its share of revenue. ZVRA kept 78.2% of revenue as net income.
ZVRA profit margins
ZVRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +350.9% | +118.8% | +51.6% | — |
| Gross profit | +455.7% | +108.4% | +49.7% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ZVRA quarterly EPS vs estimates
Zevra Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.14).
ZVRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M | $13.3M | $12.8M | $0 | $0 | $0 |
| Cost of revenue | $16.5M | $7.4M | $2.9M | $222,000 | $2.1M | $1.3M | $2.9M | $324,000 | $336,000 | $175,000 |
| Gross profit | $90.0M | $16.2M | $24.5M | $9.9M | $26.6M | $12.0M | $9.9M | −$324,000 | −$336,000 | −$175,000 |
| Research & development | $12.7M | $42.1M | $39.8M | $19.8M | $10.2M | $8.8M | $19.4M | $41.8M | $20.6M | $20.5M |
| Sales, general & admin | $77.6M | $54.9M | $24.7M | $15.6M | $8.7M | $7.9M | $10.8M | $12.5M | $12.8M | $14.0M |
| Total operating expenses | $94.2M | $103.2M | $74.1M | $52.5M | $18.9M | $17.6M | $30.2M | $54.3M | $33.4M | $34.5M |
| Operating income | −$4.2M | −$87.0M | −$49.6M | −$42.6M | $7.7M | −$5.6M | −$20.3M | −$55.9M | −$33.4M | −$37.5M |
| Interest income | $6.9M | $2.2M | $4.6M | $760,000 | $248,000 | $89,000 | $309,000 | — | — | — |
| Interest expense | $8.0M | $7.4M | $1.5M | $335,000 | $376,000 | $7.1M | $6.5M | $7.1M | $7.3M | $7.1M |
| Income before taxes | $86.7M | −$90.1M | −$46.0M | −$26.8M | −$8.5M | −$12.8M | −$24.5M | −$56.6M | −$43.4M | −$16.5M |
| Income taxes | $3.4M | $15.4M | — | −$33,000 | $34,000 | −$34,000 | −$22,000 | −$126,000 | −$43,000 | −$15,000 |
| Net income | $83.2M | −$105.5M | −$46.0M | −$26.8M | −$8.6M | −$12.8M | −$24.5M | −$56.5M | −$43.4M | −$16.5M |
| EBITDA | $98.7M | −$76.4M | −$43.5M | −$25.5M | −$7.9M | −$5.4M | −$17.7M | −$53.9M | −$33.0M | −$34.3M |
| EPS (diluted) | $0.06 | −$2.26 | −$1.29 | −$1.20 | −$2.14 | −$3.47 | −$11.84 | −$55.33 | −$42.88 | −$34.72 |
| Gross margin | 84.5% | 68.6% | 89.3% | 97.8% | 92.8% | 90.2% | 77.1% | — | — | — |
| Operating margin | −4.0% | −368.5% | −180.6% | −418.9% | 27.0% | −42.2% | −158.4% | — | — | — |
| Net margin | 78.2% | −446.9% | −167.7% | −263.5% | −29.9% | −96.0% | −191.0% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.7M | $36.2M | $34.1M | $26.1M | $25.9M | $20.4M | $12.0M | $3.7M | $4.4M | $3.4M | $2.9M | $8.5M |
| Cost of revenue | $1.5M | $2.3M | $1.5M | $1.6M | $12.4M | $1.3M | $1.4M | $2.3M | $3.6M | $3.3M | $144,000 | $677,000 |
| Gross profit | $38.1M | $34.0M | $32.6M | $24.5M | $13.5M | $19.1M | $10.7M | $1.4M | $876,000 | $160,000 | $2.8M | $7.8M |
| Research & development | $4.5M | $4.4M | $2.6M | $3.4M | $3.4M | $3.3M | $9.9M | $10.9M | $10.5M | $10.7M | $12.3M | $7.4M |
| Sales, general & admin | $16.6M | $20.8M | $20.4M | $16.9M | $20.8M | $19.5M | $16.1M | $16.2M | $12.6M | $9.9M | $5.8M | $7.0M |
| Total operating expenses | $21.4M | $25.2M | $23.3M | $20.4M | $84.5M | $24.4M | $26.1M | $28.7M | $24.7M | $20.6M | $18.1M | $14.0M |
| Operating income | $16.8M | $8.8M | $9.3M | $4.1M | −$71.0M | −$5.4M | −$15.4M | −$27.3M | −$23.8M | −$20.5M | −$15.4M | −$6.3M |
| Interest income | $2.6M | $3.6M | $1.7M | $2.3M | $2.4M | $543,000 | $73,000 | $1.0M | $270,000 | $929,000 | $1.7M | $1.6M |
| Interest expense | $0 | $1.7M | $1.9M | $2.1M | $2.0M | $2.0M | $2.2M | $2.3M | $2.1M | $735,000 | $366,000 | $197,000 |
| Income before taxes | $12.8M | $44.8M | $12.7M | −$977,000 | $76.9M | −$1.9M | −$20.4M | −$33.2M | −$19.9M | −$16.7M | −$10.2M | −$2.6M |
| Income taxes | $4.0M | $6.9M | $501,000 | −$433,000 | $2.2M | $1.2M | $15.4M | — | $70,000 | −$70,000 | $177,000 | −$74,000 |
| Net income | $8.8M | $37.9M | $12.2M | −$544,000 | $74.7M | −$3.1M | −$35.7M | −$33.2M | −$19.9M | −$16.6M | −$10.4M | −$2.6M |
| EBITDA | $13.2M | $43.5M | $15.0M | $1.5M | $80.6M | $1.7M | −$16.5M | −$29.3M | −$16.2M | −$14.4M | −$13.4M | −$2.4M |
| EPS (diluted) | $0.25 | $0.18 | $0.19 | −$0.01 | −$0.06 | −$0.06 | −$0.69 | −$0.69 | −$0.48 | −$0.40 | −$0.40 | −$0.15 |
| Gross margin | 96.2% | 93.7% | 95.5% | 94.0% | 52.2% | 93.4% | 88.7% | 37.7% | 19.7% | 4.7% | 95.0% | 92.0% |
| Operating margin | 42.3% | 24.4% | 27.3% | 15.9% | −274.5% | −26.3% | −128.0% | −739.0% | −534.8% | −598.1% | −530.7% | −73.8% |
| Net margin | 22.1% | 104.6% | 35.6% | −2.1% | 288.7% | −15.2% | −296.8% | −899.2% | −447.9% | −485.3% | −358.1% | −30.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ZVRA's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ZVRA financial results
In fiscal year 2025 (ended December 31, 2025), Zevra Therapeutics reported revenue of $106.5 million, up 350.9% from the year before. It had net income of $83.2 million, a net profit margin of 78.2%. Diluted earnings per share came to $0.06. Over five years revenue grew at an average rate of 51.6% a year.
See the ZVRA stock overview for the latest quote and news, or the ZVRA chart for price history and technical indicators.
ZVRA income statement FAQ
What is Zevra Therapeutics's annual revenue?
Zevra Therapeutics reported total revenue of $106.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 350.9% from $23.6 million the previous year.
Is Zevra Therapeutics profitable?
Yes. Zevra Therapeutics reported net income of $83.2 million in fiscal 2025, a net profit margin of 78.2%; its operating margin was −4.0%.
What is Zevra Therapeutics's gross margin?
Zevra Therapeutics's gross margin was 84.5% in fiscal 2025: for every $100 of revenue, Zevra Therapeutics kept $85 after the direct cost of its products and services.
How much does Zevra Therapeutics spend on research and development?
Zevra Therapeutics spent $12.7 million on research and development in fiscal 2025, 12.0% of revenue.
How fast is Zevra Therapeutics growing?
Revenue grew 51.6% a year on average over the last five fiscal years, from $13.3 million to $106.5 million.
What are Zevra Therapeutics's earnings per share?
Zevra Therapeutics earned $0.06 per diluted share in fiscal 2025, compared with $-2.26 a year earlier.
When will Zevra Therapeutics report its next earnings?
Zevra Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Zevra Therapeutics's fiscal year end?
Zevra Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.